FPT-SOFTWARE
1.2.2023 09:01:43 CET | Business Wire | Press release
FPT Software Europe, a subsidiary of FPT Software - leading technology and IT service provider headquartered in Vietnam, has recently announced its strategic partnership with Covestro AG (Covestro). As a leading global manufacturer of polymer materials, Covestro is included in DAX stock market index among major German companies trading on the Frankfurt Stock Exchange.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005414/en/
FPT Tower – FPT Corporation’s head quarter in Hanoi, Vietnam (Photo: Business Wire)
Entering a multi-year agreement with Covestro, FPT Software Europe is leveraging its in-depth experience, comprehensive services and best-shore model to support the DAX-listed group in the migration of 290 applications to the Amazon Web Services (AWS) cloud platform, thereby accelerating its digital transformation journey.
Starting signal for the next generation of IT infrastructure
Within the next few years, FPT Software Europe will accompany Covestro's entire transformation process. Starting with the assessment of customer requirements, the cloud experts analyze the chemical giant's legacy systems; design and implement solutions adapted to the AWS infrastructure. FPT Software Europe's core tasks in the migration process include refactoring legacy applications to preserve their functionality in the new ecosystem while leveraging the full potential of the new platform for the customer. By moving to AWS, Covestro AG is setting itself the goal of creating greater security for productive systems and business-critical workloads. Furthermore, by cloud migration, the company achieves additional benefits such as on-demand scalability of resources, increased productivity, and reduced capital and operating costs. With the move to the cloud, Covestro is laying the foundation for further digital transformation initiatives.
DAX company benefits from cloud migration expertise
FPT Software leverages its best-shore model, which is a mix of off shore, nearshore and onsite delivery to enable fast and cost-efficient processes to serve its customers like Covestro. As an AWS Advanced Partner with 600 highly qualified, certified AWS experts and around 20,000 highly trained IT specialists, FPT Software is able to implement the project in the shortest possible time and with the highest quality.
"As part of our promise to help Covestro accelerate its cloud migration, we have rapidly assembled project teams of cloud experts who work closely with the group's contacts on a day-to-day basis," said Le Hai, CEO of FPT Software Europe. "With the combined expertise of 600 certified AWS and 300 certified Microsoft experts, as well as thousands of other developers, FPT Software Europe is always ready to help European enterprises drive large-scale cloud projects and lay a solid foundation for broader digital transformation initiatives."
Through its partnership with FPT Software Europe, Covestro benefits from the comprehensive expertise of the Vietnamese IT service provider, which has already successfully implemented extensive cloud migration and digital transformation projects for major corporations like Schaeffler, RWE, Innogy and E.On.
FPT Software Europe and Covestro are discussing about further future joint projects in other areas such as managed services, cloud services with advanced application development and SAP implementation services.
About FPT Software Europe
FPT Software Europe, headquartered in Essen, Germany, is part of global technology and IT services provider FPT Software with 25,500 employees and revenue of more than $632.5 million. A pioneer in digital transformation, the company offers world-class services in Smart factory, Digital platforms, RPA (robotic process automation), Artificial Intelligence (AI), IoT (Internet of Thing), Data analytics, Mobility, Cloud, Managed services and Testing. FPT Software serves more than 1,000+ customers worldwide, 85 of which are Fortune Global 500 companies in the industries of Aerospace & Aviation, Manufacturing & Automotive, Banking Finance Insurance, Logistics & Transportation, Healthcare & Life Sciences, Retail, Utilities & Energy, and more. For more information, visit: www.fpt-europe.de.
About Covestro
Covestro is one of the world's leading manufacturers of high-quality plastics and their components. With its innovative products and processes, the company contributes to greater sustainability and quality of life in many areas. Covestro supplies global customers in key industries such as mobility, construction and housing, and electrical and electronics. In addition, Covestro's polymers are used in areas such as sports and leisure, cosmetics, healthcare and in the chemical industry itself.
The company is fully aligned with the circular economy and aims to become climate neutral by 2035 (Scope 1 and 2). In fiscal 2021, Covestro generated sales of €15.9 billion. As of the end of 2021, the company manufactures are presenting in 50 locations worldwide and employs around 17,900 people (full-time positions).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005414/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom